Dulaglutide vs Exenatide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Dulaglutide or Exenatide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Dulaglutide and Exenatide?
REWIND enrolled a broader population (31% with prior CV disease vs. 73% in EXSCEL) and still achieved significance - suggesting dulaglutide's CV benefit extends to primary prevention, while exenatide's benefit remains unproven.
Evidence Comparison
Both: FDA approved GLP-1 agonists. Dulaglutide (Trulicity): REWIND trial (Gerstein 2019, Lancet) showed HR 0.88 for MACE with broader enrollment criteria. Exenatide (Byetta/Bydureon): EXSCEL trial showed non-significant MACE reduction (HR 0.91, p=0.06). Dulaglutide has the stronger CV evidence.
Evidence Context Favoring Dulaglutide
T2DM with cardiovascular risk where a positive CVOT is clinically important for treatment selection.
Evidence Context Favoring Exenatide
T2DM where twice-daily (Byetta) or weekly (Bydureon) exenatide is preferred for cost, formulary, or specific patient factors.
Side-by-Side Snapshot
| Evidence grade | Dulaglutide: Level A Exenatide: Level A |
|---|---|
| Research status | Dulaglutide: FDA Approved Exenatide: FDA Approved |
| Primary category | Dulaglutide: Weight Loss & Metabolic Exenatide: Weight Loss & Metabolic |
| Cited studies | Dulaglutide: 3 Exenatide: 3 |